AEGON LTD. (AEG): what the price assumes

In the published model solve dated 2026-Q2, anchored at $9.14, AEGON LTD. (AEG) is priced for 11.5% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/AEG

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Solve inputs: computed at a 9.8% cost of equity with 4% terminal growth over a 10-year stage, on common book equity (FY2025).

How unusual the bet is: within-range

Valuation X-Ray

The price is supported by asset-based and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.0%); the inversion above states its own rate.

Per-Model Detail (n=5)

Solvency

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

• Aegon has been shrinking itself deliberately, retiring about 6.6% of its shares a year in the four years to the end of 2025, and in April 2026 it agreed to sell its UK arm to Standard Life for GBP 2.0 billion.
• Paying above book value asks this insurer for a sustained return on equity of about 11.8% when it has lately been earning about 10.4%, and for a life company book value is itself an estimate resting on decades-long mortality, lapse and interest assumptions.
• First-half 2026 figures land on August 20, 2026, the first set that treats the UK business as discontinued and therefore the first clean look at what the continuing group earns.

Bull Case

Mature is a description of arithmetic, not a verdict. An insurer at this stage is not going to surprise anyone with the size of its book. What it can do is earn a decent return on capital already committed and hand back the part it does not need, and Aegon has been doing the second half of that with unusual literalness. The share count fell about 6.6% a year over the four years to the end of 2025. Every surviving share owns a larger slice of the same balance sheet. That result needs no new product and no new market.

The cash does keep arriving. The group generated EUR 1.3 billion of operating capital in 2025 against a EUR 1.2 billion target, and free cash flow of EUR 829 million against a target of about EUR 800 million. It returned EUR 1.1 billion to shareholders over the year through dividends and repurchases, and proposed a final dividend that lifted the full-year 2025 payout to EUR 0.40 per common share. For a business whose regulated subsidiaries hold the money, that sequence is the honest signal: capital was generated inside the operating entities, travelled up to the holding company, and then left it.

April 2026 added a second lever. Aegon agreed to sell Aegon UK to Standard Life for GBP 2.0 billion, taking GBP 0.75 billion in cash plus 181.1 million Standard Life shares, roughly 15.3% of the enlarged buyer, with the cash earmarked for a mix of debt reduction and further repurchases. On the company's own pro-forma arithmetic the deal adds about EUR 1.1 billion to group shareholders' equity. A smaller group carrying more capital behind each remaining share is the shape the entire plan is driving toward.

What is left after that is concentrated in the United States, and management has been paying to clean it up rather than letting it sit. Aegon reinsured part of Transamerica's secondary guarantee universal life block during 2025, moving some of the oldest and most capital-hungry guarantees off its own balance sheet. Legacy blocks of that kind are where life insurers hide their worst economics, and each one removed makes the reported return a closer description of the business actually being run.

None of this asks the buyer to believe a growth story, which is the quiet strength of the position. Peer-multiple approaches and earnings-power approaches both land at or above where the shares trade. The price sits about 17% above where the asset-value methods land, roughly what a modest premium to book implies. The methods that land furthest below the price are the forward-growth ones, and they get there by extending a revenue line that keeps falling because the group keeps selling businesses, not because the businesses it keeps are decaying.

The obvious objection is that the price still asks for a better return than the company is currently earning, and the gap is real: a bit over a point of return on equity. It is worth sizing that gap honestly. Returns for a life insurer move with interest rates, with the mix of guarantees carried, and with how much surplus capital sits idle in the subsidiaries. A group that has been removing legacy guarantees, selling a whole national business at a price it likes, and retiring stock every year has three ordinary ways to close a gap of that size. It does not need a heroic outcome.

Bear Case

Whoever buys these shares today is not buying the company that will exist in three years. The plan set out at the December 2025 Capital Markets Day moves the head office and legal seat to the United States, switches the reporting basis to US GAAP, and retires the Aegon name in favour of Transamerica, targeted for January 1, 2028, at one-time implementation costs of around EUR 350 million spread over the intervening years. Four months later the company agreed to sell its UK business. Buying above book value into a balance sheet still being rearranged is a different proposition from buying a settled one, and the price does not obviously distinguish between the two.

Set the corporate geography aside and the arithmetic is plain. An insurer is worth more than its capital only when it earns more on that capital than the capital costs. Today's price assumes a sustained return on equity of about 11.8%. The recent run rate is about 10.4%. Over one year that difference is noise. Sustained over the horizon that supports a premium to book, it is the difference between a premium and none, and if the return settles where the company has actually been earning, the multiple of book the price can support compresses toward book itself.

Underneath that sits a subtler problem: book value for a life insurer is not a bank balance. It is what remains after decades of assumptions about how long policyholders live, how many lapse, what the invested assets earn, and what the guarantees end up costing. MET's own annual report states the judgment involved without decoration: The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. Every US life insurer revisits those assumptions on a schedule, and the revisions land in earnings and in equity. The denominator of the return the price is counting on is itself an estimate.

The business that remains also competes for the same savings dollars as considerably larger balance sheets. PRU's FY2025 annual report describes its institutional retirement market this way: We compete with other large, well-established insurance companies, asset managers and diversified financial institutions primarily based on pricing, structuring capabilities, and states the consequence directly: Our profitability is substantially impacted by our ability to appropriately price our products. In a market where price is the competitive variable, the participant with the strongest balance sheet and the lowest cost of capital sets the terms. A mid-sized US life and retirement operation is not usually that participant.

Then there is the size of what is left. Before the UK sale the company described a 2025 operating result run-rate of EUR 1.5 to 1.7 billion; afterwards the pro-forma 2025 run-rate is EUR 1.3 to 1.5 billion, growing at around 5% a year through 2027. The sale also takes roughly five percentage points off the group solvency ratio before any deleveraging or repurchases. Selling a business well and buying stock with the proceeds is a defensible use of capital. It is not the same thing as earning more, and the shrinking share count has to keep outrunning the shrinking earnings base for the arithmetic to work. The price has already assumed it does.

Valuation

Start with the bar the price sets. At $9.14 the shares change hands above book value, and for an insurer a premium to book is a claim about return on capital rather than about the assets behind it. That premium corresponds to a sustained return on equity of about 11.8%, against roughly 10.4% recently earned. The bar is also soft in one specific way. It is calculated against a required return near 9.9%, and each percentage point added to or taken from that required return moves the bar about 1.3 points in the same direction. A reader who believes capital is cheaper than that is looking at a lower bar; one who believes it is dearer is looking at a higher one.

The methods used to triangulate the shares disagree in a way that is informative rather than alarming. Peer-multiple approaches and earnings-power approaches both land at or above where the stock trades. The price sits about 17% above where the asset-value methods land, close to what a modest premium to book implies on its own. The forward-growth methods sit furthest below, with the price roughly 56% above where they land, because they project the business forward from a top line that has been contracting. That contraction is mostly the arithmetic of disposals rather than decay in the operations retained, so the pattern reads as a value-supported price rather than a growth bet.

The approaches that land furthest above the shares deserve their own caveat. They work by taking recent per-share earnings growth and carrying it forward, and per-share earnings growth here has been flattered twice: once by a share count that fell every year, and again by an earnings line that swings with the accounting of a group in the middle of selling things. Those readings mark the outer edge of the range, not its middle.

Against its peer group the shares sit in the lower half on price to book, which is consistent with a company whose earnings base is about to get smaller on purpose. The balance-sheet test for an insurer is not debt coverage. Policy reserves and float are the funding, so what matters is regulatory capital and how much of what the subsidiaries earn is allowed to leave them. On that test 2025 read well: EUR 1.1 billion went back to shareholders against a EUR 980 million net result for the year. Returning more than a year's earnings is only sustainable while capital keeps being released from legacy blocks and disposals, which is precisely what the next two years are scheduled to do, and precisely what stops when they are done.

Catalysts

The next fixed point is August 20, 2026, when Aegon publishes first-half 2026 figures. Those accounts are the first to carry the UK business as held for sale and as discontinued operations, which makes them the first clean view of what the continuing group earns and the first test of the rebased run-rate management has guided toward.

The sale itself is the larger event. Announced on April 15, 2026, it transfers Aegon UK to Standard Life for GBP 2.0 billion, made up of GBP 0.75 billion in cash and 181.1 million Standard Life shares representing about 15.3% of the enlarged buyer, and is expected to close around the end of 2026 subject to regulatory approvals. The company has said the cash proceeds go to a combination of deleveraging and share repurchases. On a pro-forma 2025 basis it puts the effect at about EUR 1.1 billion on group shareholders' equity and about EUR 0.6 billion on the group net result, with roughly five percentage points off the solvency ratio before those proceeds are deployed. Two details will matter at closing: whether the Standard Life stake is held or sold down, and how fast the cash turns into repurchases.

Further out sits the corporate move unveiled at the Capital Markets Day of December 10, 2025: head office and legal seat to the United States, reporting switched to US GAAP, the group renamed Transamerica, a target date of January 1, 2028, and alongside all of it a EUR 400 million buyback for 2026 and an ambition to raise the dividend per share by more than 5% a year. The accounting change deserves more attention than it usually gets. Moving from IFRS to US GAAP re-measures the same liabilities on different rules, and the first restated set of numbers is where any surprise about the size of the equity base would show up.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• WTW (WILLIS TOWERS WATSON PLC)
• FY2025 10-K: …substantially impact our results. While it is difficult to predict the consequences of any deterioration in global economic conditions on our business, any significant reduction or delay by our clients in purchasing our services or insurance or making payment of premiums could have a material adverse impact on our…
• FY2025 10-K: …declines in premiums, may significantly undermine our profitability. Because we do not determine the timing or extent of premium pricing changes, it is difficult to accurately forecast our commission revenue, including whether they will significantly decline. As a result, we may have to adjust our plans for future…
• RNR (RENAISSANCERE HOLDINGS LTD)
• FY2025 10-K: …and commercial insurance across the United States. COMPETITION The markets in which we operate are highly competitive. Our competitors include independent reinsurance and insurance companies, subsidiaries, divisions and/or affiliates of globally recognized insurance companies, domestic and international underwriting…
• FY2025 10-K: …of our management team, our integrated and flexible underwriting and operating platform, our significant financial strength, our strong relationships with brokers, customers and capital partners, our commitment to superior service and our proprietary modeling technology. By consistently applying each of our three…
• PUK (PUK)
• FY2025 20-F: …to show on a basis that includes the Group's share of joint ventures and associates, together with a further breakdown of the movement in insurance and reinsurance contract balances by segment. The difference in most cases between the notes in C3.2 and C3.3 is solely the addition of the amounts of joint ventures and…
• FY2025 20-F: …CSM. The Group recognises the allocated amount, adjusted for interest accretion, as insurance revenue and an equal amount as insurance service expenses. Non-distinct investment components are excluded from insurance revenue and insurance service expenses. Policy fees charged on investment contracts without DPF for…
• AFG (AMERICAN FINANCIAL GROUP, INC.)
• FY2025 10-K: …negative effect not only on AFG's business in that market but also on AFG's reputation generally. RISKS RELATING TO THE INSURANCE INDUSTRY Intense competition could adversely affect AFG's results of operations. The property and casualty insurance segment operates in a highly competitive industry that is affected by…
• FY2025 10-K: …the property and inland marine and crop insurance operations was 68 Table of Contents partially offset by lower underwriting profitability in the transportation businesses. Catastrophe losses were $66 million (2.3 points on the combined ratio), including $1 million in net reinstatement premiums, in 2024 compared to…
• VOYA (Voya Financial, Inc.)
• FY2025 10-K: …performance, investment philosophy and process, product features and structure and client service. Our principal competitors include insurance-owned asset managers such as Principal Global Investors (Principal Financial Group), Prudential and Ameriprise and bank-owned asset managers such as "pure-play" asset managers…
• FY2025 10-K: ◦ Our ability to increase or maintain our market share in highly competitive markets. ◦ Our ability to achieve the desired results from recent acquisitions. ◦ The complexity of our products and services and our reliance on intermediaries. ◦ A deterioration in our AUM or the alteration or termination of our asset…
• GNW (GENWORTH FINANCIAL, INC.)
• FY2025 10-K: …our results of operations, capital levels, RBC levels and financial condition would be materially adversely affected absent future premium rate increases and associated benefit reductions, and implementing other reduced benefit options. Our policyholders may not react as anticipated to our in-force rate increases. In…
• FY2025 10-K: …in-force and risk in-force for our Enact segment. Insurance in-force is a measure of the aggregate unpaid principal balance as of the respective reporting date for loans insured by our U.S. mortgage insurance subsidiaries. Risk in-force is based on the coverage percentage applied to the estimated current outstanding…
• UNM (Unum Group)
• FY2025 10-K: …Condition and Results of Operations - Ratings" contained herein in Item 7 for our current outlook, issuer credit, and financial strength ratings. See also further discussion in "Risk Factors" contained herein in Item 1A. 13 T able of Contents Competition There is significant competition among insurance companies for…
• FY2025 10-K: …a decrease in our other expense ratio. Within our Unum Poland line of business, we expect to drive growth by continuing to expand our existing distribution channels. We will also continue to invest in digital capabilities, technology, and product enhancements, which we believe will drive sustainable growth over the…
• AIZ (Assurant, Inc.)
• FY2025 10-K: , including changes in frequency and severity, and the impact of inflation, also contribute to fluctuations in our business performance. In addition, across many of our businesses, we must respond to competitive pressures, including the threat of disruption and competition for talent. For more information on these and…
• FY2025 10-K: We must respond to the threat of disruption by traditional players, such as insurers, from new entrants, such as "Insurtech" companies, and from their use of technologies such as AI. Competition in each business is based on a number of factors, including scope of products and services offered, ability to tailor…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.